Cabaletta Bio FY2025 EPS Forecast Boosted by William Blair

Cabaletta Bio, Inc. (NASDAQ:CABA) – Investment analysts at William Blair raised their FY2025 earnings per share estimates for shares of Cabaletta Bio in a research note issued on Monday, November 10th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($2.15) per share for the year, up from their prior estimate of ($2.37). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. William Blair also issued estimates for Cabaletta Bio’s Q4 2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($1.91) EPS.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.05.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a report on Friday, October 10th. Jefferies Financial Group initiated coverage on shares of Cabaletta Bio in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald increased their target price on Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.11.

Cabaletta Bio Price Performance

Cabaletta Bio stock traded down $0.08 during midday trading on Thursday, reaching $2.37. The stock had a trading volume of 353,263 shares, compared to its average volume of 2,218,851. The firm has a market cap of $228.14 million, a price-to-earnings ratio of -0.94 and a beta of 3.10. Cabaletta Bio has a twelve month low of $0.99 and a twelve month high of $5.46. The firm’s fifty day simple moving average is $2.40 and its two-hundred day simple moving average is $1.91.

Institutional Investors Weigh In On Cabaletta Bio

Institutional investors and hedge funds have recently made changes to their positions in the business. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Cabaletta Bio during the second quarter valued at approximately $32,000. CRA Financial Services LLC increased its stake in Cabaletta Bio by 36.4% in the third quarter. CRA Financial Services LLC now owns 15,000 shares of the company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in Cabaletta Bio during the third quarter valued at about $47,000. Callan Family Office LLC bought a new position in Cabaletta Bio during the 1st quarter valued at approximately $58,000. Finally, Comerica Bank increased its stake in shares of Cabaletta Bio by 2,292.1% during the first quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after purchasing an additional 39,860 shares in the last quarter.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.